| Title |
The Prevalence and Cost of Unapproved Uses of Top-Selling Orphan Drugs
|
|---|---|
| Published in |
PLOS ONE, February 2012
|
| DOI | 10.1371/journal.pone.0031894 |
| Pubmed ID | |
| Authors |
Aaron S. Kesselheim, Jessica A. Myers, Daniel H. Solomon, Wolfgang C. Winkelmayer, Raisa Levin, Jerry Avorn |
| Abstract |
The Orphan Drug Act encourages drug development for rare conditions. However, some orphan drugs become top sellers for unclear reasons. We sought to evaluate the extent and cost of approved and unapproved uses of orphan drugs with the highest unit sales. |
X Demographics
The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 33% |
| Italy | 1 | 17% |
| Unknown | 3 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 5 | 83% |
| Science communicators (journalists, bloggers, editors) | 1 | 17% |
Mendeley readers
The data shown below were compiled from readership statistics for 85 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 2% |
| Brazil | 1 | 1% |
| Netherlands | 1 | 1% |
| India | 1 | 1% |
| Luxembourg | 1 | 1% |
| Unknown | 79 | 93% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 16 | 19% |
| Student > Master | 12 | 14% |
| Student > Ph. D. Student | 10 | 12% |
| Other | 10 | 12% |
| Student > Postgraduate | 8 | 9% |
| Other | 17 | 20% |
| Unknown | 12 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 27 | 32% |
| Pharmacology, Toxicology and Pharmaceutical Science | 12 | 14% |
| Agricultural and Biological Sciences | 5 | 6% |
| Immunology and Microbiology | 4 | 5% |
| Social Sciences | 4 | 5% |
| Other | 16 | 19% |
| Unknown | 17 | 20% |